BioXcel raises ~$6.2M in public offering of stock and warrants; cash runway into Q1 2025

BioXcel Therapeutics, Inc.

Issued 5.6M shares and warrants, plus 9M pre-funded warrants, at $0.48 per share (or $0.479 for pre-funded).
Net proceeds of ~$6.2M after underwriting discounts; use for SERENITY At-Home and TRANQUILITY In-Care trials.
Cash runway expected into Q1 2025 when combined with existing cash; potential need for additional capital.
Exercise price of 8.5M previously issued warrants reduced to $0.571 per share on Nov 21, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.